CytomX Therapeutics

Yahoo Finance • 2 months ago

CytomX Therapeutics to Present at Upcoming December Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the followin... Full story

Yahoo Finance • 2 months ago

CytomX Therapeutics to Present at the Jefferies London Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive off... Full story

Yahoo Finance • 2 months ago

CytomX outlines Q1 2026 CX-2051 data update and 100-patient enrollment milestone as Phase Ib study nears

Earnings Call Insights: CytomX Therapeutics (CTMX) Q3 2025 MANAGEMENT VIEW * CEO Sean McCarthy announced the appointment of Rachael Lester as Chief Business Officer, emphasizing her "broad strategic planning and business development ex... Full story

Yahoo Finance • 2 months ago

CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

- CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025 supportive of ongoing Phase 1 combinat... Full story

Yahoo Finance • 2 months ago

CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial resu... Full story

Yahoo Finance • 3 months ago

CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Rachael Lester as Senior Vice... Full story

Yahoo Finance • 5 months ago

CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

- May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) - - CX-2051 Phase 1 dose expansions on track for data update in Q... Full story

Yahoo Finance • 5 months ago

CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025

SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report second quarter f... Full story

Yahoo Finance • 6 months ago

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

NetworkNewsWire Editorial Coverage NEW YORK, July 9, 2025 /CNW/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease worldwide, a toll that is projected to rise in th... Full story

Yahoo Finance • 7 months ago

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive offi... Full story

Yahoo Finance • 8 months ago

CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025

SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial resul... Full story

Yahoo Finance • 10 months ago

CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

- Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in 1H 2025 - - CX-801 (PROBODY® Interferon-alpha 2b) Phase 1a... Full story

Yahoo Finance • 10 months ago

CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive of... Full story

Yahoo Finance • 2 years ago

CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1 dose escalation data anticipated in the first half of 2024 - - CX-2051 (EpCAM-directed ADC) comprehensive preclinical profile presented at 14th Annual World ADC Conference; IND filing on... Full story

Yahoo Finance • 2 years ago

CytomX Therapeutics to Present at Upcoming November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that management will participate in the follo... Full story

Yahoo Finance • 2 years ago

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual Meeting

- IND filing for CX-801 anticipated by the end of 2023 - SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, tod... Full story

Yahoo Finance • 2 years ago

CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference

- CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sensitivity with a topoisomerase-1 inhibitor payload - - Preclinical data demonstrate a favorable predicted therapeutic index and effi... Full story

Yahoo Finance • 2 years ago

CytomX Therapeutics to Present at Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that management will participate in the foll... Full story

Yahoo Finance • 3 years ago

CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.

- Financing is expected to extend cash runway into the 2nd half of 2025 based on current operating plans, enabling the Company to reach multiple clinical milestones - - $30 million initial investment and up to $90 million in total potenti... Full story

Yahoo Finance • 3 years ago

CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023

SOUTH SAN FRANCISCO, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it will report first quarter financial re... Full story